Ferritin is the body's main iron storage protein, so its level generally mirrors total body iron stores. When stores are low, ferritin falls, making a low ferritin a reliable sign of iron deficiency. However, ferritin is also an acute-phase reactant: during inflammation, its level rises even if iron stores are not increased. This means that a high ferritin can reflect inflammation or iron overload, and a normal or even high ferritin during inflammation does not rule out iron deficiency. Inflammation can therefore mask iron deficiency by elevating ferritin, while very low ferritin still points to depleted iron stores. That combination—low ferritin indicating deficiency, and elevated ferritin potentially signaling inflammation or overload—best captures how ferritin should be interpreted when inflammation is present. Ferritin does not indicate vitamin B12 status, nor is it a direct measure of transferrin saturation, and its levels are not immune to inflammatory changes, all of which are why the statement described is the most accurate.

When evaluating hypercalcemia, the first key test is the parathyroid hormone level. In the presence of high calcium, PTH should be suppressed. If PTH is elevated or remains inappropriately normal (not suppressed) despite hypercalcemia, the parathyroid gland is driving the process. This points to PTH-dependent causes such as primary hyperparathyroidism (and related states where PTH remains active despite high calcium). If the PTH level is suppressed, the hypercalcemia is more likely due to PTH-independent mechanisms, such as malignancy-associated hypercalcemia (PTHrP), vitamin D–mediated processes, or granulomatous disease, where calcium is elevated through non-PTH pathways. Thus, an elevated or inappropriately normal PTH with hypercalcemia best indicates PTH-dependent etiologies, whereas suppressed PTH points to PTH-independent causes.

Shelf life of evacuated tubes is defined by the stability of the additive and the integrity of the vacuum. The additive (such as EDTA, citrate, heparin, or a clot activator) must stay chemically and functionally stable for the duration of the stated shelf life, so it continues to preserve or anticoagulate the sample as intended. If the additive degrades, the blood may clot or the chemistry may be altered, compromising test results. At the same time, the vacuum in the tube must be retained; a loss of vacuum can allow air ingress or improper blood-to-additive ratios, leading to inconsistent fill volumes, dilution effects, or premature clotting. Both factors together determine how long the tube can reliably be used while delivering accurate and reproducible results.

The prothrombin time assesses the extrinsic pathway of coagulation and the common pathway. It uses tissue factor (thromboplastin) and calcium to trigger clot formation and primarily reflects the function of factors II, V, VII, and X (with VII being vitamin K–dependent and having a short half-life). A prolonged PT or INR means there is reduced activity of these factors. This can occur with liver dysfunction (where clotting factors are synthesized), vitamin K deficiency (needed to activate these factors), or warfarin therapy (which inhibits vitamin K–dependent factor activation). INR is used to standardize PT results across laboratories. It’s not a test of the intrinsic pathway (that’s measured by the aPTT) and it doesn’t directly assess platelets or kidney function.